µÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
µÏÍþÖƵÏÍþ¹ú¼Ê | Ê¥ÂÞÀ³?Á½ÏîÑо¿³É¹ûÁÁÏàASN 2025£¬ÐÄѪ¹Ü°²È«ÐÔÓÅÊÆÔÙÌíÁ¦Ö¤
·¢²¼ÈÕÆÚ£º2025/11/05
×ÖºÅ

2025Äê11ÔÂ5~9ÈÕ£¬µÚ58½ìÃÀ¹úÉöÔಡѧ»áÄê»áÃÀ¹úÉöÔàÖÜ (ASN Kidney Week 2025)ÔÚÃÀ¹úÐÝ˹¶Ù¾ÙÐС£Óڴ˹æÄ£×î´ó¡¢Ñ§Êõˮƽ×î¸ßµÄ¹ú¼ÊÉöÔಡѧÊõÊ¢»á£¬µÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄ´´ÐµÏÍþ¹ú¼ÊÅàĪɳëÄ£¨ÉÌÆ·Ãû£ºÊ¥ÂÞÀ³?£©£¬¹²ÓÐÁ½ÏîÑо¿³É¹ûÈëÑ¡²¢ÒÔ±Ú±¨ÐÎʽ¹«²¼¡£

¸ÃÁ½ÏîÑо¿·Ö±ð´Ó»úÖƺÍÁÙ´²½Ç¶È£¬Ö¤ÊµÁËÅàĪɳëÄÔÚʵÏÖѪºìµ°°×£¨Hb£©¸ß´ï±êÂʵÄͬʱ£¬»¹¾ßÓÐÁ¼ºÃµÄÐÄѪ¹Ü°²È«ÐÔ£¬ÒÔ¼°¾ßÓÐÐÄÔà±£»¤×÷ÓÃ[1,2]¡£


»úÖÆÑо¿¡ª¡ª

½ÒʾÅàĪɳëľßÓÐDZÔÚÐļ¡±£»¤×÷ÓÃ


Ò»ÏîÓɱ±¾©´óѧÈËÃñÒ½ÔºÉöÄÚ¿ÆÍŶӿªÕ¹µÄÑо¿£¬½ÒʾÁËÅàĪɳëĵÄÐļ¡±£»¤×÷ÓûúÖÆ[1]¡£¸ÃÑо¿µÄÍêÕûÄÚÈÝÒÑÓÚ½üÆÚ·¢±íÔÚ¡¶¹ú¼ÊÃâÒßµÏÍþ¹ú¼ÊÀíѧ¡·ÔÓÖ¾(International Immunopharmacology£¬IF 4.7)¡£Ñо¿ÀûÓÃH9c2Ðļ¡Ï¸°ûÄ£ÐÍ£¬Ö¤Ã÷ÁËÅàĪɳëÄÄܹ»Í¨¹ýÒÖÖÆCD131±í´ï¡¢×è¶ÏEPOR-CD131Òì¶þ¾ÛÌåµÄÐγÉ£¬½ø¶ø×è¶ÏJAK2/STAT3ͨ·µÄ¼¤»î£¬´Ó¶øÓÐЧ»º½âÁòËáßÅßá·Ó£¨IS£©ÓÕµ¼µÄÐļ¡Ï¸°û·Ê´ó[3]¡£

ÕâΪÅàĪɳëÄDZÔڵݲȫÐÔÓÅÊÆ£¨ÀýÈç¼õÉÙÐÄѪ¹Ü²»Á¼Ê¼þ£©¼°Æä¶ÀÌصÄÐÄÔà±£»¤ÌØÐÔ£¬ÌṩÁËÓÐÁ¦µÄ»úÖÆÒÀ¾Ý¡£





IIIÆÚÑо¿Êºó·ÖÎö¡ª¡ª

ÔÙ´Î֤ʵÅàĪɳëľßÓнµµÍÐÄѪ¹Ü·çÏÕµÄDZÔÚ»ñÒæ


¼ÈÍù·¢±íµÄIIIÆÚÁÙ´²Ñо¿½á¹ûÏÔʾ£¬ÎÞÂÛÊÇ͸ÎöÈËȺ»¹ÊÇ·Ç͸ÎöÈËȺ£¬ÅàĪɳëÄ×éµÄ¸´ºÏ°²È«ÐÔʼþ£¨°üÀ¨È«ÒòËÀÍö¡¢×äÖкÍÐļ¡¹£ËÀ£©ºÍÆäËûÐÄѪ¹Üʼþ£¨°üÀ¨ÐèҪסԺÖÎÁƵIJ»Îȶ¨ÐĽÊÍ´ºÍÐèҪסԺÖÎÁƵÄÐÄÁ¦Ë¥½ß£©·¢ÉúÂʾùµÍÓÚ¶ÌЧ´ÙºìËØ×é[4,5]¡£ASN 2024·¢²¼µÄÒ»ÏîÕë¶Ô͸ÎöÈËȺµÄIIIÆÚÑо¿Êºó·ÖÎö»¹ÏÔʾ£¬ÅàĪɳëÄ×éµÄ¸ßѪѹ¡¢¸Î¶¾ÐԺ͸߼ØѪ֢·¢ÉúÂÊÒ²¾ùµÍÓÚ¶ÌЧ´ÙºìËØ×é[6]¡£

±¾´ÎASN´ó»á·¢²¼µÄÁíÒ»Ïî»ùÓÚÁ½¸öIIIÆÚÁÙ´²Ñо¿(NCT03902691£¬NCT03903809)µÄʺó·ÖÎö£¬½øÒ»²½ÆÀ¹ÀÁËÅàĪɳëĵÄÁÆЧºÍÐÄѪ¹Ü°²È«ÐÔ¡£ÎÞÂÛÔÚ͸Îö»¹ÊÇ·Ç͸ÎöÈËȺÖУ¬ÅàĪɳëľùÄÜʹ¾ø´ó¶àÊý£¨¡Ý87%£©µÄ»¼ÕßʵÏÖHb¡Ý10g/dL£¬´ï±êÂʾù¸ßÓÚ¶ÌЧ´ÙºìËضÔÕÕ×飬ÇÒÖ÷ÒªÐÄѪ¹Ü²»Á¼Ê¼þ(5P-MACE£º°üÀ¨ÐÄѪ¹ÜËÀÍö¡¢Ðļ¡¹£ËÀ¡¢×äÖС¢²»Îȶ¨ÐÔÐĽÊÍ´¼°ÐèסԺµÄÐÄÁ¦Ë¥½ß)ºÍÀ©Õ¹ÐÄѪ¹ÜʼþµÄ·¢ÉúÂʾùÒ»Ö¸üµÍ¡£ÆäÖУ¬Í¸Îö»¼ÕßÖУ¬ÅàĪɳëÄÏà±È¶ÔÕÕ×éµÄ5P-MACE·çÏÕϽµ65%(HR 0.35,95%CI 0.11-1.10)£»·Ç͸Îö»¼ÕßÖÐÔòÏà±È¶ÔÕÕ×éϽµ86%(HR 0.14,95%CI 0.02-1.28)¡£ÌáʾÅàĪɳëÄÏà±È¶ÌЧ´ÙºìËؾßÓнµµÍÐÄѪ¹Üʼþ·çÏÕµÄDZÔÚ»ñÒæ[2]¡£


ƶѪ»áÔö¼ÓCKD»¼ÕßÐÄѪ¹Üʼþ¼°ËÀÍöµÄ·çÏÕ[7]£¬Òò´Ë£¬»ý¼«¿ØÖÆƶѪÊÇCKD¹ÜÀíµÄÖØÒª×é³É²¿·Ö¡£´«Í³µÄ¶ÌЧ´ÙºìËØÔÚÎÒ¹úÉöÐÔƶѪÁìÓòÒѹ㷺ʹÓöàÄ꣬µ«ÓÐÑо¿ÏÔʾÆä»áÔö¼ÓÐÄѪ¹ÜʼþÉõÖÁËÀÍö·çÏÕ[8]¡£Òò´Ë£¬ÉöÐÔƶѪµÄÖÎÁƵÏÍþ¹ú¼ÊÎïÔÚ×·ÇóHb´ï±êµÄͬʱ»¹Ó¦¼æ¹Ë°²È«ÐÔ¡£

ÅàĪɳëÄÄ¿Ç°ÒÑÔ½À´Ô½¹ã·ºµØÓÃÓÚCKDÏà¹ØƶѪµÄÖÎÁÆ£¬²¢Ïà¼Ì»ñµÃ¡¶³¤Ð§ºìϸ°ûÉú³É´Ì¼¤¼ÁÖÎÁÆÉöÐÔƶѪÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©¡·[9]¡¢¡¶Ö¸µ¼ÉöÐÔƶѪ»¼Õß×ÔÎÒ¹ÜÀíµÄÖйúר¼Ò¹²Ê¶(2024 °æ)¡·[10]ÒÔ¼°¡¶ÑÓ»ºÂýÐÔÉöÔಡ½øÕ¹ÁÙ´²¹ÜÀíÖ¸ÄÏ£¨2025Äê°æ£©¡·[11]µÄÍƼöÈÏ¿É¡£

±¾´ÎASN´ó»áÒÔ¼°¼ÈÍù·¢±íµÄÏà¹ØÑо¿¾ù֤ʵÁËÅàĪɳëľßÓÐÈ·ÇеĿ¹Æ¶ÑªÁÆЧºÍÁ¼ºÃµÄÐÄѪ¹Ü°²È«ÐÔ£¬Õ⽫ÓÐÖúÓÚ¸ÄÉÆÉöÐÔƶѪµÄ³¤ÆÚ¹ÜÀí£¬ÊµÏÖƶѪµÄÎȶ¨³ÖÐø¿ØÖÆ£¬¸ÄÉÆCKD»¼ÕßµÄÉú´æÔ¤ºó¡£

²Î¿¼ÎÄÏ×£º

1.Zhang, Xinyu,et al.Pegmolesatide Ameliorates Indoxyl Sulfate-Induced Cardiomyocyte Hypertrophy Through Modulating the EPOR-CD131-Dependent JAK2/STAT3 Signaling Pathway. ASN 2025. Abstract: TH-PO0288

2.Chen Jianghua, et al. Efficacy and Cardiovascular Safety of Pegmolesatide in Renal Anemia: Post Hoc Analysis of Two Phase 3 Trials. ASN 2025. Abstract: FR-PO0199

3.Zhang X, Li S, Lin T,et al.Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2/STAT3 signaling pathway.Int Immunopharmacol. 2025 Oct 14;167:115643.

4.Ping Zhang, et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. EClinicalMedicine. 2023 Oct 28; 65:102273

5.Xie J, et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD. Kidney Int Rep. 2024 Dec 6;10(3):720-729.

6.Chen Jianghua,et al.Pegmolesatide for the Treatment of Anemia in Patients with CKD Undergoing Dialysis: Insights from a Randomized Active-Controlled Phase 3 Study. ASN 2024. ABSTRACT: TH-PO888

7.ÖйúÉöÐÔƶѪÕïÖÎÁÙ´²Êµ¼ùÖ¸ÄÏ. ÖлªÒ½Ñ§ÔÓÖ¾,2021,101(20):1463-1502.

8.Palmer SC, et al.Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010 Jul 6;153(1):23-33.

9.³¤Ð§ºìϸ°ûÉú³É´Ì¼¤¼ÁÖÎÁÆÉöÐÔƶѪÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©. ÖлªÉöÔಡÔÓÖ¾,2024,40(2):146-157.

10.Ö¸µ¼ÉöÐÔƶѪ»¼Õß×ÔÎÒ¹ÜÀíµÄÖйúר¼Ò¹²Ê¶(2024 °æ). ÖйúѪҺ¾»»¯.2025,24(1):1-12

11.ÑÓ»ºÂýÐÔÉöÔಡ½øÕ¹ÁÙ´²¹ÜÀíÖ¸ÄÏ£¨2025Äê°æ£©. ÖлªÉöÔಡÔÓÖ¾,2025,41(6):455-488.

¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£¹«Ë¾Á¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ£¬ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£

ÃâÔðÉùÃ÷

±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾ÎÄÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£

Ç°Õ°ÐÔ˵Ã÷

±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿